logo

Cost and time-effective universal medical device for treatment of onychomycosis by combining several technologies

Sector: Hospital • Location: Spain

Source: EU Funding & Tenders Portal

Project
Ended

TERMOSALUD, S.L., hereinafter TSALUD, is an Spanish SME whose core business is Well-being, Health and Medical–Esthetic industry. Currently, TSALUD goal is the development of specialized medical equipment oriented to dermatology within Medical–Esthetic business line: new Derma business line. OZONELASER project is oriented to create a new product within “Derma” field in order to provide dermatogolog

Status
Closed
Sector
Hospital, Commercial
Location
Spain
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Cost and time-effective universal medical device for treatment of onychomycosis by combining several technologies

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Cost and time-effective universal medical device for treatment of onychomycosis by combining several technologies” is an infrastructure initiative in the Hospital sector, located in Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

TERMOSALUD, S.L., hereinafter TSALUD, is an Spanish SME whose core business is Well-being, Health and Medical–Esthetic industry. Currently, TSALUD goal is the development of specialized medical equipment oriented to dermatology within Medical–Esthetic business line: new Derma business line. OZONELASER project is oriented to create a new product within “Derma” field in order to provide dermatogological treatments (for nails, skins or hairs) and diagnosis for a fungal infection (onychomycosis or OM) based on cell technologies. While competitors use treatment solutions based on drugs or on (high or low) laser technologies, OZONELASER will be the unique commercial product based on a combination of two technologies which provides high efficiency, low prizes, universality on the type of patient to be treated, short treatment periods, painless and natural tissue regeneration by fostering own body cells growth. Likewise, patients cannot develop resistance to OZONELASER while they do to current existing treatments based on antifungals. Thus, OZONELASER will provide a solution for treatment and diagnosis of a fungal infection on finfernails and toenails which affects 10% of worldwide population, specially on elderly which in 2060 it will represent around the 50% of worldwide population and only in USA it represents a 16 billion € market. In addition, TSALUD has a long-term strategy for such Derma business line. This will be further improved through new developments. TSALUD bases this New Market Strategy on SME Instrument to reduce OZONELASER time to market (accelerate startegic partner selection, collection of user needs, IPR protection, etc.) as it is known how medical devices require long-term developments due to clinical trials

Location

Country

Spain

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Commercial

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project